COVID-19 vaccine (Ad26.COV2-S [recombinant])


Entry
D12129                      Drug                                   
Name
COVID-19 vaccine (Ad26.COV2-S [recombinant]);
Janssen COVID-19 vaccine;
Ad26.COV2.S;
Covid-19 vaccine Janssen (TN);
Jcovden (TN)
Product
  Other
JANSSEN COVID-19 VACCINE (Janssen Products)
Class
Antiviral
 DG03172  COVID-19 vaccine
Remark
Therapeutic category: 6313
ATC code: J07BX03
Product: D12129<JP/US>
Efficacy
Active immunization (SARS-CoV-2)
  Disease
Prevention of COVID-19 [DS:H02398]
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko05171  Coronavirus disease - COVID-19
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J07 VACCINES
   J07B VIRAL VACCINES
    J07BX Other viral vaccines
     J07BX03 Covid-19 vaccines
      D12129  COVID-19 vaccine (Ad26.COV2-S [recombinant]) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   631  Vaccines
    6313  Viral vaccines
     D12129  COVID-19 vaccine (Ad26.COV2-S [recombinant])
Drug groups [BR:br08330]
 Antiviral
  DG03172  COVID-19 vaccine
   D12129  COVID-19 vaccine (Ad26.COV2-S [recombinant])
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12129
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12129
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12129
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12129